US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities
Recommendation

10/11 February 2026
Risk analysis, preventive measures and incident management
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
28.01.2026IPEC: Revised REACH Guide for Excipients
28.01.2026EDQM: New General Chapter 'Quality of Data' available
21.01.2026FDA Warning Letter: Q-Unit failed to document API release
14.01.2026Testing for ethylene glycol, diethylene glycol and methanol – a hot topic during FDA inspections
14.01.2026APIC: Update to the Data Integrity FAQs


